Ahuja, N, Cole, AJ (2009) Hyperthermia syndromes in psychiatry. Advances in Psychiatric Treatment, 15: 181–91.
Boyer, E, Shannon, M (2005) The serotonin syndrome. New England Journal of Medicine, 352: 1112–20.
Buckley, AB, Dawson, AH, Isbister, GK (2014) Serotonin syndrome. BMJ, 348: g1626.
Cauli, O, Morelli, M (2005) Caffeine and the dopaminergic system. Behavioural Pharmacology, 16: 63–77.
Chander, WP, Singh, N, Mukhiya, GK (2011) Serotonin syndrome in maintenance haemodialysis patients following sertraline treatment for depression. Journal of the Indian Medical Association, 109: 36–7.
Chang, TW, Castle, DJ (2004) Layer upon layer, thermoregulation in schizophrenia. Schizophrenia Research, 69: 149–57.
Chechani, V (2002) Serotonin syndrome presenting as hypotonic coma and apnoea: potentially fatal complications of selective serotonin reuptake inhibitor therapy. Critical Care Medicine, 30: 473–6.
Cooper, BE, Sejnowski, CA (2013) Serotonin syndrome: recognition and treatment. AACN Advanced Critical Care, 24: 15–20.
Copeland, J, Dillon, P, Gascoigne, M (2006) Ecstasy and the concomitant use of pharmaceuticals. Addictive Behaviors, 31: 367–70.
Demyttenaere, K, Haddad, P (2000) Compliance with antidepressant therapy and antidepressant discontinuation symptoms. Acta Psychiatrica Scandinavica Supplementum, 403: 50–6.
Dunkley, EJC, Isbister, GK, Sibbritt, D et al (2003) The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM, 96: 635–42.
Ener, RA, Sharon, B, Meglathery, MD et al (2003) Serotonin syndrome and other serotonergic disorders. Pain Medicine, 4: 63–74.
Evans, RW, Tepper, SJ, Shapiro, RE et al (2010) The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache, 50: 1089–99.
Ferrari, A (2006) Headache: one of the most common and troublesome adverse reactions to drugs. Current Drug Safety, 1: 34–58.
Fox, MA, Jensen, CL, Gallagher, PS et al (2007) Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice. Neuropharmacology, 53: 643–56.
Fugate, JE, White, RD, Rabinstein, AA (2014) Serotonin syndrome after therapeutic hypothermia for cardiac arrest: a case series. Resuscitation, 85: 774–7.
Gillman, PK (2005) Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95: 434–41.
Gillman, PK (2010a) Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache, 50: 264–72.
Gillman, PK (2010b) CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. Journal of Psychopharmacology, 25: 429–36.
Haddad, PM, Dursun, SM (2008) Neurological complications of psychiatric drugs: clinical features and management. Human Psychopharmacology: Clinical and Experimental, 23: 15–26.
Hegerl, U, Bottlender, R, Gallinat, J et al (1998) The serotonin syndrome scale: first results on validity. European Archives of Psychiatry and Clinical Neuroscience, 248: 96–103.
Herraiz, T, Chapparo, C (2006) Human monoamine oxidase inhibition by coffee and beta-carbolines norharman and harman isolated from coffee. Life Sciences, 78: 795–802.
Iqbal, MM, Miles, JB, Kaplan, J et al (2012) Overview of serotonin syndrome. Annals of Clinical Psychiatry, 24: 310–18.
Isbister, IK, Buckley, NA, Whyte, IM (2007) Serotonin toxicity: a practical guide to diagnosis and treatment. Medical Journal of Australia, 187: 361–5.
Jacobs, BL (1974) Effect of two dopamine receptor blockers on a serotonin-mediated behavioural syndrome in rats. European Journal of Pharmacology, 27: 363–6.
Jones, SL, Athan, E, O'Brien, D (2004) Serotonin syndrome due to co-administration of linezolid and venlafaxine. Journal of Antimicrobial Chemotherapy, 54: 289–90.
Kiani, J, Imam, SZ (2007) Medicinal importance of grapefruit juice and its interactions with various drugs. Nutrition Journal, 6: 33.
Krishnamoorthy, S, Ma, Z, Zhang, G et al (2010) Involvement of 5-HT2A receptors in the serotonin syndrome caused by excessive 5-HT efflux in the rat brain. Clinical Pharmacology and Toxicology, 107: 830–41.
Lane, RM (1998) SSRI-induced extrapyramidal side effects and akathisia: implications for treatment. Journal of Psychopharmacology, 12: 192–214.
Lee, AJ, Chan, WK, Harralson, AF et al (1999) The effects of grapefruit juice on sertraline metabolism: an in vitro and in vivo study. Clinical Therapeutics, 21: 1890–9.
Lee, YC, Chen, PP (2010) A review of SSRIs and SNRIs in neuropathic pain. Expert Opinion on Pharmacotherapy, 11: 2813–25.
Lingam, R, Scott, J (2002) Treatment non-adherence in affective disorders. Acta Psychiatrica Scandinavica, 105: 164–72.
Lynch, T, Price, A (2007) The effect of cytochrome P450 metabolism on drug response, interactions and adverse effects. American Family Physician, 76: 391–6.
Monte, A, Chuang, R, Bodmer, M (2010) Dextromethorphan, chlorpheniramine and serotonin toxicity: case report and systemic literature review. British Journal of Clinical Pharmacology, 70: 794–8.
Morris, R, Matthes, J (2015) Serotonin syndrome in a breast-fed neonate. BMJ Case Reports, DOI: 10.1136/bcr-2015–209418 (published online 6 May).
Morrish, PK (2014) Serotonin syndrome. BMJ, 348: g1626.
Odagaki, Y (2009) Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?
Current Drug Safety, 4: 84–93.
Okamoto, N, Sakomoto, K, Yamada, M (2012) Transient serotonin syndrome by concurrent use of electroconvulsive therapy and selective serotonin reuptake inhibitor: a case report and review of the literature. Case Reports in Psychiatry, 2012: article ID 215214.
Park, SH, Wackermah, RC, Stimmel, GL (2014) Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants?
Journal of Pharmacy Practice, 27: 71–8.
Prakash, S, Belani, P, Trivedi, A (2014) Headache as a presenting feature in patients with serotonin syndrome: a case series. Cephalalgia, 34: 148–53.
Radomski, JW, Dursun, SM, Reveley, MA et al (1999) An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Medical Hypotheses, 55: 218–24.
Shaikh, Z, Krueper, S, Malins, T (2011) Serotonin syndrome: take a close look at the unwell surgical patient. Annals of The Royal College of Surgeons of England, 93: 569–72.
Shee, JC (1960) Dangerous potentiation of pethidine by iproniazid and its treatment. BMJ, 2: 507–9.
Shioda, K, Nisijima, K, Nishida, S et al (2004) Possible serotonin syndrome arising from an interaction between caffeine and serotonergic antidepressants. Human Psychopharmacology: Clinical and Experimental, 19: 353–4.
Silins, E, Copeland, J, Dillon, P (2007) Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. Australian & New Zealand Journal of Psychiatry, 41: 649–55.
Steele, D, Keltner, NL, McGuiness, TM (2011) Are neuroleptic malignant syndrome and serotonin syndrome the same syndrome?
Perspectives in Psychiatric Care, 47: 58–62.
Sternbach, H (1991) The serotonin syndrome. American Journal of Psychiatry, 148: 705–13.
Sun-Edelstein, C, Tepper, SJ, Shapiro, RE (2008) Drug-induced serotonin syndrome: a review. Expert Opinion on Drug Safety, 7: 587–96.
Tomaselli, G, Modestin, J (2004) Repetition of serotonin syndrome after re-exposure to SSRI: a case report. Journal of Pharmacopsychiatry, 37: 236–8.
Volpie-Abadie, J, Kaye, A, Kaye, D (2013) Serotonin syndrome. Ochsner Journal, 13: 533–40.
Zhou, S, Chan, E, Pan, SQ (2004) Pharmacokinetic interactions of drugs with St John's Wort. Journal of Psychopharmacology, 18: 262–76.
Zhou, SF (2009) Polymorphisms of human cytochrome P450 2D6 and its clinical significance: Part 1. Clinical Pharmacokinetics, 48: 689–723.
Serotonin syndrome: a spectrum of toxicity
eLetters
No eLetters have been published for this article.